Research progress of immunotherapy for advanced head and neck cancer

被引：1

作者：

Sun, Anchi ^{[1
,2
]}

Xing, Zhiwei ^{[1
]}

Lv, Rongrong ^{[1
]}

Niu, Pengyuan ^{[3
]}

Zhao, Bao ^{[1
,4
]}

Ma, Shiyin ^{[1
]}

Li, Hui ^{[1
]}

机构：

[1] Bengbu Med Univ, Dept Otolaryngol, Affiliated Hosp 1, Bengbu 233004, Anhui, Peoples R China

[2] Anhui Engn Technol Res Ctr Biochem Pharmaceut, 2600 Donghai Ave, Bengbu 233030, Anhui, Peoples R China

[3] Bengbu Med Univ, Dept Neurosurg, Affiliated Hosp 1, Bengbu 233004, Anhui, Peoples R China

[4] Hefei Comprehens Natl Sci Ctr, Inst Hlth & Med, Hefei 230071, Peoples R China

来源：

MEDICAL ONCOLOGY | 2024年 / 41卷 / 06期

基金：

中国国家自然科学基金;

关键词：

Head and neck cancer; Immunotherapy; Immune evasion; Combination therapy; Advanced tumors; SQUAMOUS-CELL CARCINOMA; LOCALLY ADVANCED HEAD; METASTATIC HEAD; PHASE-II; T-CELLS; RECURRENT; DURVALUMAB; PEMBROLIZUMAB; CETUXIMAB; ANTIGENS;

D O I：

10.1007/s12032-024-02375-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Head and neck cancer accounts for about one-fifth of all malignant tumors, and the incidence is increasing year by year. The overall mortality rate was high and the 5-year survival rate was low. At present, the combination of surgery, radiotherapy, and chemotherapy is the main treatment in clinical practice, but the treatment of recurrent or metastatic advanced head and neck cancer is still a challenge. With the rise of immunotherapy, more and more studies on immune checkpoint inhibitors have been conducted. This review summarizes the mechanism, clinical application and safety of immunotherapy for advanced head and neck cancer.

引用

页数：7

共 45 条

[1] Biochemical Signaling of PD-1 on T Cells and Its Functional Implications [J].

Boussiotis, Vassiliki A. ;

Chatterjee, Pranam ;

Li, Lequn .

CANCER JOURNAL, 2014, 20 (04) :265-271

[2]

Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI [10.3322/caac.21492, 10.3322/caac.21609]

[3] Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study [J].

Burtness, Barbara ;

Harrington, Kevin J. ;

Greil, Richard ;

Soulieres, Denis ;

Tahara, Makoto ;

de Castro, Gilberto, Jr. ;

Psyrri, Amanda ;

Baste, Neus ;

Neupane, Prakash ;

Bratland, Ase ;

Fuereder, Thorsten ;

Hughes, Brett G. M. ;

Mesia, Ricard ;

Ngamphaiboon, Nuttapong ;

Rordorf, Tamara ;

Ishak, Wan Zamaniah Wan ;

Hong, Ruey-Long ;

Mendoza, Rene Gonzalez ;

Roy, Ananya ;

Zhang, Yayan ;

Gumuscu, Burak ;

Cheng, Jonathan D. ;

Jin, Fan ;

Rischin, Danny .

LANCET, 2019, 394 (10212) :1915-1928

[4] NKG2A Immune Checkpoint in Vδ2 T Cells: Emerging Application in Cancer Immunotherapy [J].

Cazzetta, Valentina ;

Depierreux, Delphine ;

Colucci, Francesco ;

Mikulak, Joanna ;

Mavilio, Domenico .

CANCERS, 2023, 15 (04)

[5] Impact of lymphopenia on efficacy of nivolumab in head and neck cancer patients [J].

Cesaire, Mathieu ;

Rambeau, Audrey ;

Clatot, Florian ;

Johnson, Alisson ;

Heutte, Natacha ;

Thariat, Juliette .

EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 2023, 280 (05) :2453-2461

[6] Improved Immunoregulation of Ultra-Low-Dose Silver Nanoparticle-Loaded TiO2 Nanotubes via M2 Macrophage Polarization by Regulating GLUTI and Autophagy [J].

Chen, Yangmengfan ;

Guan, Ming ;

Ren, Ranyue ;

Gao, Chenghao ;

Cheng, Hao ;

Li, Yong ;

Gao, Biao ;

Wei, Yong ;

Fu, Jijiang ;

Sun, Jun ;

Xiong, Wei .

INTERNATIONAL JOURNAL OF NANOMEDICINE, 2020, 15 :2011-2026

[7] Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort [J].

Chow, Laura Q. M. ;

Haddad, Robert ;

Gupta, Shilpa ;

Mahipal, Amit ;

Mehra, Ranee ;

Tahara, Makoto ;

Berger, Raanan ;

Eder, Joseph Paul ;

Burtness, Barbara ;

Lee, Se-Hoon ;

Keam, Bhumsuk ;

Kang, Hyunseok ;

Muro, Kei ;

Weiss, Jared ;

Geva, Ravit ;

Lin, Chia-Chi ;

Chung, Hyun Cheol ;

Meister, Amy ;

Dolled-Filhart, Marisa ;

Pathiraja, Kumudu ;

Cheng, Jonathan D. ;

Seiwert, Tanguy Y. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (32) :3838-+

[8] Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study [J].

Cohen, Ezra E. W. ;

Soulieres, Denis ;

Le Tourneau, Christophe ;

Dinis, Jose ;

Licitra, Lisa ;

Ahn, Myung-Ju ;

Soria, Ainara ;

Machiels, Jean-Pascal ;

Mach, Nicolas ;

Mehra, Ranee ;

Burtness, Barbara ;

Zhang, Pingye ;

Cheng, Jonathan ;

Swaby, Ramona F. ;

Harrington, Kevin J. .

LANCET, 2019, 393 (10167) :156-167

[9]

Coley W B, 1891, Ann Surg, V14, P199, DOI 10.1097/00000658-189112000-00015

[10] Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy [J].

Coulie, Pierre G. ;

Van den Eynde, Benoit J. ;

van der Bruggen, Pierre ;

Boon, Thierry .

NATURE REVIEWS CANCER, 2014, 14 (02) :135-146

← 1 2 3 4 5 →